Canfosfamide

Drug Profile

Canfosfamide

Alternative Names: Telcyta; TER 286; TLK 286

Latest Information Update: 10 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Telik
  • Class Antineoplastics; Oligopeptides; Small molecules
  • Mechanism of Action Glutathione transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer
  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 10 Jul 2013 Canfosfamide is still available for licensing. http://www.telik.com
  • 05 Apr 2013 Telik terminates phase II trial in Diffuse large B cell lymphoma, Mantle cell lymphoma and Multiple myeloma in the USA (NCT01148108)
  • 31 Mar 2013 Suspended - Phase-II for Diffuse large B cell lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top